Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07473778 · ClinicalTrials.gov registry record
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
A clinical trial, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- 3,000
- Enrollment target
NCT07473778: Recruiting study, sponsored by Gilead Sciences.
NCT07473778 is a clinical trial that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 3,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07473778 is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
Study Summary
The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine clinical practice when LEN is added as PrEP option and will evaluate persistence on LEN PrEP. The primary objective of this study is to evaluate real-life persistence on LEN PrEP at Week 52 in diverse clinical settings in the United States.
Primary Outcome
LEN PrEP persistence at Week 52 is defined as the proportion of participants receiving a LEN injection at enrollment who had an on-time injection at Week 26 and an on-time Week 52 visit ('on time' is defined as ≤ 28 weeks from the last injection).
Interventions
- DRUG Lenacapavir Injection
- DRUG Lenacapavir Tablet
- DRUG Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
- DRUG Cabotegravir (CAB)
- DRUG Emtricitabine/tenofovir alafenamide (F/TAF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2026-03-17 |
| Est. Completion | 2029-04 |
What NCT07473778 shows while recruiting
NCT07473778 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 5 interventions - of which Lenacapavir Injection is the first listed.
NCT07473778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07473778 about?
NCT07473778 is a clinical study titled "Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention". The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine c...
What is the current status of trial NCT07473778?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2026-03-17. Estimated completion is 2029-04.
What interventions are being tested in trial NCT07473778?
The interventions under investigation include: Lenacapavir Injection (DRUG), Lenacapavir Tablet (DRUG), Emtricitabine/tenofovir disoproxil fumarate (F/TDF) (DRUG), Cabotegravir (CAB) (DRUG), Emtricitabine/tenofovir alafenamide (F/TAF) (DRUG).
Who is sponsoring clinical trial NCT07473778?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI